Current incidence and future projections of fragility hip fractures in Sri Lanka.

Arch Osteoporos

Department of Anatomy, Faculty of Medicine, University of Ruhuna, Matara, Sri Lanka.

Published: November 2020

Unlabelled: IN SRI LANKA, THE CRUDE AND STANDARDIZED HIP FRACTURE RATES IN 2018 WERE 88.3 AND 115.5 PER 100,000 PERSON-YEARS, RESPECTIVELY. IN 2018, 3824 HIP FRACTURES WOULD HAVE OCCURRED IN THE COUNTRY AND THIS IS LIKELY TO REACH 12,068 IN 2051: PURPOSE: This study was designed to calculate the current crude, standardized, and age- and sex-specific fragility hip fracture incidence in Sri Lanka and hip fracture projection for 2051. Currently such data are not available.

Methods: New fragility hip fractures (resulting from falls from standing height or less) that occurred in the Southern province of Sri Lanka from Sep 2017 to 2018 were collected prospectively by visiting and contacting all health care centers that provide care for fracture patients. Traumatic fractures, old fractures, and fractures among residents outside Southern province were excluded. We calculated current crude, standardized (US standardized population 2000), and age- and sex-specific fragility hip fracture incidence. The number of hip fractures that would occur in 2051 was estimated based on the population projections of the country.

Results: There were 554 patients admitted during 1-year period from September 2017 giving crude hip fracture incidence of 88 per 100,000 person-years (95% CI 85-90). The crude hip fracture rates among women and men were 132.2 and 35.3 per 100,000 person-years, respectively. The standardized hip fracture rate was 115.5 per 100,000 person-years. According to the data, 3824 (95% CI 3200-4583) hip fractures would have occurred island-wide during the study period. This number is likely to reach 12,068 (95% CI 10405-13,990) in 2051 when the age-specific population projections are taken into consideration.

Conclusions: Although the observed hip fracture rate was low when compared with other countries, the number of hip fracture would increase from the current 10 per day to around 33 in 2051.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11657-020-00848-8DOI Listing

Publication Analysis

Top Keywords

hip fracture
36
hip fractures
20
fragility hip
16
sri lanka
16
100000 person-years
16
hip
14
crude standardized
12
fracture incidence
12
fracture
10
fractures
8

Similar Publications

Objectives: To evaluate the association between heart rate on admission and mortality in elderly patients with hip fractures.

Design: A retrospective cohort study.

Setting: At a trauma centre in northwestern China.

View Article and Find Full Text PDF

Clinical experience with denosumab discontinuation.

Osteoporos Int

January 2025

Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.

Unlabelled: In patients receiving long-term treatment with denosumab, denosumab discontinuation via sequential treatment with zoledronate, resulted in a minor decrease in bone mass density (BMD) of 0-2.5% within the first year and stabile BMD in the second year, thus showing that repeated treatments with zoledronate limit the loss of BMD, when discontinuing denosumab.

Purpose: Discontinuing denosumab (DMAb) rapidly decreases bone mineral density (BMD) and increases the risk of multiple vertebral fractures.

View Article and Find Full Text PDF

Unlabelled: This population study investigated the association between birth characteristics and fracture risk in 11,099 young adults (aged 19-54 years). Our findings indicate that birth weight, gestational age, and birth weight for gestational age were not associated with fractures in the wrist, humerus, hip, and spine in this population.

Purpose: Skeletal development starts during fetal life, and it is estimated that most bone formation occurs in the 3rd trimester.

View Article and Find Full Text PDF

Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study.

Osteoporos Int

January 2025

School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Unlabelled: Most subjects in osteoporosis clinical trials were women with postmenopausal osteoporosis and while bridging studies (BMD endpoint) provide an expectation that osteoporosis medications will reduce fracture risk in men. This real-world study shows direct evidence of fracture risk reduction among men with osteoporosis (36% of hip fracture reduction with denosumab).

Purpose: Direct evidence for fracture risk reduction of medications used among men with osteoporosis is very limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!